Research

Hormonal

Blocking myostatin/activin signaling (via ActRIIB blockade) promotes muscle hypertrophy and can reverse cancer cachexia by inhibiting SMAD2/3 signaling and stimulating SMAD1/5/8 pathways.

For those struggling with severe muscle loss, such as in cancer cachexia, therapies that block myostatin/activin signaling show promise in preserving and even increasing muscle mass. This approach targets the root cause of excessive muscle breakdown rather than just stimulating synthesis.

GoodSupportsHIGH confidence
Moreover, blocking TGFβ signaling through the administration of a soluble receptor (ActRIIB) was able to rescue muscle mass under several atrophic models, reverse cancer cachexia, and, remarkably, delay mortality independently of tumor progression [62].
Anna Vainshtein et al. · International Journal of Molecular Sciences · 2020

Why this rating

The paper cites multiple studies showing consistent effects in various atrophic models, including cancer cachexia, though human clinical data is still evolving.

Source

Signaling Pathways That Control Muscle Mass

Anna Vainshtein et al. · International Journal of Molecular Sciences · 2020

DOI 10.3390/ijms21134759

narrative_reviewCited 210×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →